Literature DB >> 9762946

Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy.

P M Anderson1, G Schroeder, K M Skubitz.   

Abstract

BACKGROUND: Mouth sores and/or difficulty swallowing are common and painful consequences of cytotoxic chemotherapy for cancer. In previous studies oral glutamine was found to protect animals from the effects of whole abdominal radiation and methotrexate-induced enteritis. Glutamine also was found to reduce oral mucositis in a nonrandomized pilot study in humans. Therefore, the authors attempted to determine the efficacy of oral glutamine in a randomized, double blind, crossover trial in cancer patients receiving chemotherapy.
METHODS: Twenty-four patients (16 children and 8 adults) received glutamine or placebo (glycine) suspension (2 g amino acid/M2/dose twice daily) to swish and swallow on days of chemotherapy administration and for at least 14 additional days. Patients completed a calendar indicating days of mouth pain associated with each chemotherapy course and the effect of mouth pain on oral intake.
RESULTS: Paired data indicated significant amelioration of stomatitis associated with glutamine administration after chemotherapy. The duration of mouth pain was 4.5 days less in chemotherapy courses in which glutamine supplementation was compared with placebo (Wilcoxon's signed rank test, P=0.0005). The severity of oral pain also was reduced significantly when glutamine was provided with chemotherapy (the amount of days mucositis restricted oral intake to soft foods [> or =Grade 2; Modified Eastern Cooperative Oncology Group grading system] was 4 days less with glutamine compared with placebo; Wilcoxon's signed rank test, P=0.002).
CONCLUSIONS: Low dose oral glutamine supplementation during and after chemotherapy significantly reduced both the duration and severity of chemotherapy-associated stomatitis. Oral glutamine appears to be a simple and useful measure to increase the comfort of many patients at high risk of developing mouth sores as a consequence of intensive cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9762946     DOI: 10.1002/(sici)1097-0142(19981001)83:7<1433::aid-cncr22>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

Review 1.  Interventions for preventing oral mucositis for patients with cancer receiving treatment.

Authors:  Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

Review 2.  Novel therapeutic approaches in pediatric and young adult sarcomas.

Authors:  Peter M Anderson; Margaret Pearson
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 3.  Immune-modulating enteral formulations: optimum components, appropriate patients, and controversial use of arginine in sepsis.

Authors:  Minhao Zhou; Robert G Martindale
Journal:  Curr Gastroenterol Rep       Date:  2007-08

Review 4.  Measurement of oral mucositis in children: a review of the literature.

Authors:  Deborah Tomlinson; Peter Judd; Eleanor Hendershot; Anne-Marie Maloney; Lillian Sung
Journal:  Support Care Cancer       Date:  2007-08-28       Impact factor: 3.603

5.  Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements.

Authors:  Noam Yarom; Allan Hovan; Paolo Bossi; Anura Ariyawardana; Siri Beier Jensen; Margherita Gobbo; Hanan Saca-Hazboun; Abhishek Kandwal; Alessandra Majorana; Giulia Ottaviani; Monica Pentenero; Narmin Mohammed Nasr; Tanya Rouleau; Anna Skripnik Lucas; Nathaniel Simon Treister; Eyal Zur; Vinisha Ranna; Anusha Vaddi; Karis Kin Fong Cheng; Andrei Barasch; Rajesh V Lalla; Sharon Elad
Journal:  Support Care Cancer       Date:  2019-07-08       Impact factor: 3.603

Review 6.  Radiotherapy-Specific Chronic Pain Syndromes in the Cancer Population: An Evidence-Based Narrative Review.

Authors:  Jay Karri; Laura Lachman; Alex Hanania; Anuj Marathe; Mani Singh; Nicholas Zacharias; Vwaire Orhurhu; Amitabh Gulati; Alaa Abd-Elsayed
Journal:  Adv Ther       Date:  2021-02-11       Impact factor: 3.845

7.  Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

Authors:  Jerry R Greenfield; I Sadaf Farooqi; Julia M Keogh; Elana Henning; Abdella M Habib; Anthea Blackwood; Frank Reimann; Jens J Holst; Fiona M Gribble
Journal:  Am J Clin Nutr       Date:  2008-12-03       Impact factor: 7.045

8.  Targeted Therapy of Ewing's Sarcoma.

Authors:  Vivek Subbiah; Pete Anderson
Journal:  Sarcoma       Date:  2010-10-31

Review 9.  Glutamine as indispensable nutrient in oncology: experimental and clinical evidence.

Authors:  Katharina S Kuhn; Maurizio Muscaritoli; Paul Wischmeyer; Peter Stehle
Journal:  Eur J Nutr       Date:  2009-11-21       Impact factor: 5.614

10.  [Circadian rhythm of PCA-based opioid consumption in children with chemotherapy-related mucositis].

Authors:  C Schiessl; I Schestag; N Griessinger; R Sittl; B Zernikow
Journal:  Schmerz       Date:  2009-02       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.